Bernard-Valnet R - Search Results

1

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.

Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D. Zéphir H, et al. J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21. J Neurol. 2015. PMID: 26194198

2

Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.

Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir H, Cavillon G, Rogemond V, Casey R, Frangoulis B, De Sèze J, Vukusic S, Honnorat J, Confavreux C; NOMADMUS Study Group. Marignier R, et al. Neurology. 2013 Jun 11;80(24):2194-200. doi: 10.1212/WNL.0b013e318296e917. Epub 2013 May 8. Neurology. 2013. PMID: 23658379

3

An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays.

Höftberger R, Sabater L, Marignier R, Aboul-Enein F, Bernard-Valnet R, Rauschka H, Ruiz A, Blanco Y, Graus F, Dalmau J, Saiz A. Höftberger R, et al. PLoS One. 2013 Nov 4;8(11):e79083. doi: 10.1371/journal.pone.0079083. eCollection 2013. PLoS One. 2013. PMID: 24223884 Free PMC article.

4

[Evolution of Devic's neuromyelitis optica spectrum disorders].

Bernard-Valnet R, Marignier R. Bernard-Valnet R, et al. Presse Med. 2015 Apr;44(4 Pt 1):401-10. doi: 10.1016/j.lpm.2014.05.030. Epub 2014 Dec 18. Presse Med. 2015. PMID: 25535163 French.

5

Neuromyelitis optica: a positive appraisal of seronegative cases.

Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R. Bernard-Valnet R, et al. Eur J Neurol. 2015 Dec;22(12):1511-8, e82-3. doi: 10.1111/ene.12679. Epub 2015 Feb 16. Eur J Neurol. 2015. PMID: 25689634 Review.

6

Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications.

Cobo-Calvo Á, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, Martínez-Yélamos S, Saiz A, Marignier R. Cobo-Calvo Á, et al. Mult Scler. 2016 Mar;22(3):312-9. doi: 10.1177/1352458515591071. Epub 2015 Jul 24. Mult Scler. 2016. PMID: 26209592

7

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.

Bernard-Valnet R, Pignolet B, Biotti D, Ciron J, Lafontan JF, Dumas H, Bonneville F, Brassat D. Bernard-Valnet R, et al. Mult Scler Relat Disord. 2018 Oct;25:216-218. doi: 10.1016/j.msard.2018.08.006. Epub 2018 Aug 7. Mult Scler Relat Disord. 2018. PMID: 30114625

8

Area postrema syndrome: Another feature of anti-GFAP encephalomyelitis.

Ciron J, Sourdrille F, Biotti D, Tchoumi T, Ruiz A, Bernard-Valnet R, Maubeuge N, Marignier R. Ciron J, et al. Mult Scler. 2020 Feb;26(2):253-255. doi: 10.1177/1352458518817992. Epub 2019 Jan 21. Mult Scler. 2020. PMID: 30663514

9

Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.

Bernard-Valnet R, Cobo-Calvo A, Siegfried A, Marasescu R, Bonnan M, Ballan G, Ellie E, Bauer J, Uro-Coste E, Marignier R, Brassat D. Bernard-Valnet R, et al. Mult Scler Relat Disord. 2019 Jun;31:97-100. doi: 10.1016/j.msard.2019.03.031. Epub 2019 Apr 1. Mult Scler Relat Disord. 2019. PMID: 30954932

10

CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments.

Bernard-Valnet R, Moisset X, Maubeuge N, Lefebvre M, Ouallet JC, Roumier M, Lebrun-Frenay C, Ciron J, Biotti D, Clavelou P, Godeau B, Du Pasquier RA, Martin-Blondel G. Bernard-Valnet R, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 2;9(1):e1097. doi: 10.1212/NXI.0000000000001097. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34728496 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page